INTRODUCTION
How long an individual expects to live-their perceived life expectancy-reflects their disease understanding and the medical profession's ability to prognosticate for and communicate with them. Perceived life expectancy may affect a variety of outcomes, including healthcare choices. Patients with incurable lung and colon cancer who thought they were going to live for at least 6 months were more likely to favour lifeextending therapy over comfort care compared with patients who thought there was at least a 10% chance that they would not live 6 months. 1 Critically unwell inpatients who do not expect to live 2 months are less likely to opt for cardiopulmonary resuscitation in the event of sudden death than individuals who perceive their prognosis to be better. 2 Prognosis communication has been widely studied in oncology, and the majority of people with cancer want detailed prognostic information, presented honestly and openly. 3 However, non-cancer chronic disease causes more deaths than cancer worldwide, with cardiovascular disease being the biggest killer. 4 Almost 2.3 million people in the UK have a diagnosis of coronary heart disease, and over half a million have heart failure (HF). 5 An estimated 1.2 million people have a diagnosis of chronic obstructive pulmonary disease (COPD) 6 and almost 60 000 receive renal replacement therapy for end-stage
Strengths and limitations of this study
▪ This is the first review of perceived life expectancy among patients with chronic non-cancer disease. ▪ The findings build on and reproduce the oncology literature showing patients with cancer have a tendency to overestimate their life expectancy and chances of cure. ▪ The findings of this review are based on the small number of studies that have been conducted on this subject. ▪ The literature was only available for patients with heart failure, end-stage renal failure and chronic obstructive pulmonary disease.
renal failure (ESRF). 7 Life expectancy for patients with chronic disease including advanced COPD, HF and ESRF can be as poor as that seen in incurable cancer. [8] [9] [10] Lately, there has been a practice shift away from paternalistic medicine. Shared decision-making empowers individuals and their carers to make choices about what care they want based on honest, open disclosure of the known benefits and risks of proposed treatment options. 11 Decisions to accept treatment with invasive therapies such as ventilation, dialysis and implanted cardiac defibrillator placement may be influenced by how long individuals expect to live. Patients facing such decisions can only be considered fully informed if they have an understanding of their prognosis and the effects available treatments might have on it. Up to 38% of patients near the end of life receive treatment administered with little or no hope of it having any effect, largely because of the underlying state of the patient's health and the known or expected poor prognosis regardless of treatment. 12 Quality of end-of-life care is significantly better for patients with cancer than for patients with ESRF or HF, largely due to higher rates of palliative care review and lower rates of intensive care admission and cardiopulmonary resuscitation among individuals with malignancy. 13 It is possible that suboptimal end of life treatment is partly driven by unrealistic expectations of prognosis.
Many patients with cancer, including those with incurable disease, report never discussing prognosis with their healthcare team, misunderstand whether their condition is curable and overestimate their expected survival. 3 No systematic analysis of perceived life expectancy among individuals with non-cancer chronic disease has been performed. This review was conducted to evaluate what is known about how long patients with non-cancer chronic disease expect to live and how these estimates compare with other methods of predicting survival and measured outcomes.
METHODS

Search strategy
A systematic search of MEDLINE, Embase, PsychINFO and the Cochrane Library was conducted up to and including September 2016. Abstracts of unpublished works were searched using ProQuest dissertations and theses search and the Networked Digital Library of Theses and Dissertations Global ETD search. Search terms relating to 'life expectancy' and 'self-estimated' were used (see online supplementary appendix A). Search results were limited to humans and English language.
Inclusion and exclusion criteria Non-cancer chronic disease was defined as any longterm illness that is associated with reduced life expectancy, but not caused by cancer or infection. Conditions included were HF; chronic kidney disease stage 5 (CKD); ESRF receiving dialysis or conservative care; diabetes mellitus; COPD; interstitial lung disease; neurodegenerative disease and liver cirrhosis. Studies were included where adults (≥18 years of age) with these conditions were asked to estimate their life expectancy. All measurements of life expectancy were accepted, including those in terms of duration (eg, "How long do you expect to live"), and chance (eg, "What is the chance you will be alive in five years"). Studies were excluded where only self-estimated probability of 'cure' was determined, where the only option for survival duration was <6 months and where participants were asked to consider only hypothetical situations (eg, "How long do you think you would live if you had a kidney transplant"). Studies reporting only on participants with cancer, HIV/AIDS, congenital heart disease, cystic fibrosis and organ transplant were excluded. In all these conditions the situation, illness culture or advances in treatment may have affected how generalisable findings were to the larger chronic disease population. At the title and abstract searching phase, articles assessing prognosis in excluded diagnoses were not rejected, so that reference list searches could be performed from these papers. Where studies reported a mixture of included and excluded diagnoses, they were incorporated if the data on individual diseases were reported separately. Where data were not separately reported, authors were contacted to request online supplementary files. Data were extracted from figures and tables in papers, where needed.
Study selection process
Titles were independently examined by two reviewers (BH and JS) according to the above criteria and a Kappa statistic calculated to assess agreement. Abstracts from titles accepted by either one or both reviewers were collected and assessed independently, using the same criteria, and included if both recommended inclusion. Where only one reviewer recommended inclusion, a consensus decision was made after discussion. Full text articles were requested and read and reference lists were examined with additional papers included by the same criteria. At this point, papers reporting excluded disease groups were rejected. Disagreement between authors was addressed by discussion and a consensus decision reached in all cases.
Quality assessment
No suitable tool to grade the quality of included literature could be found. A quality assessment tool (see online supplementary appendix B) was developed by the authors to assess and grade the quality of available literature based on semiobjective assessment of factors influencing the generalisability, risk of bias and reporting quality of included literature. This tool has not been previously validated. Papers included for review were independently graded by the authors and a mean score taken to categorise each as low, medium or high quality.
The study was registered with the PROSPERO database, registration number CRD42015020732.
RESULTS
The initial search provided 6837 titles after removal of duplicates. 249 abstracts were selected for review by either one or both authors (agree to exclude, 6588; agree include, 158; disagree, 91; κ 0.77). Thirty-one articles were collected, and reference list searching provided an additional eight. After full text examination of 39 articles, seven papers and two conference abstracts were included in the review (figure 1). No unpublished works met the inclusion criteria. Two of the included papers originate from a single study. 14 15 A complete list of papers including reasons for inclusion/rejection is available (see online supplementary appendix C). Evidence was graded as medium quality in four and low quality in three of the included papers (table 1) . No articles were graded as high quality. The two abstracts were not quality assessed as insufficient information was available.
Studies came from the UK, 18 Netherlands 17 and USA. 14 16 19-22 A total of 729 participants were included (HF, 573; COPD, 89; ESRF, 62; CKD, 5) with study sizes ranging from 20 to 135 patients (see table 1 ). Four papers reported on a single medical disease; HF 16 17 19 21 22 and ESRF. 20 Others reported on a mixture of conditions; HF and COPD 14 15 and HF, CKD and COPD. 18 No papers reporting on non-COPD lung disease, neurodegenerative disease or cirrhosis were found. The mean age of study participants ranged from 58 to 75. In the study by Fried et al 14 15 only individuals over 60 years of age were recruited and only those over 50 in the study by Kraai et al. 17 No minimum age was set in the other studies. Two studies did not include selection criteria for disease severity, 16 17 and selection criteria were unreported in one study. 21 In all other studies, criteria were used to select for patients with advanced disease. Patients with ESRF were all receiving outpatient haemodialysis. 20 Reported levels of comorbidity were high. The mean Charlson Comorbidity Index for patients with ESRF was 5.8 (SD 1.6). 20 Among US patients with HF in one study, 82% had hypertension, 54% diabetes and 29% COPD. 16 Among patients with HF from the Netherlands, 57% had hypertension, 30% had diabetes, 24% had COPD and 11% had a stroke. 17 One study used a written questionnaire to measure self-estimated life expectancy. 19 Methodology was unreported in two studies. 21 22 All other studies used interviews. Participants with ESRF were asked about their chances of being alive at different time points. 20 In the other studies, participants were asked to indicate how long they expected to live by selecting from vignette answers, 18 giving a verbal response [14] [15] [16] and/or by using a Visual Analogue Scale. 16 17 In one study, it was not possible to ascertain how the question had been posed or answered. 19 For studies where data were available, large numbers of initially eligible patients were excluded from Follow-up periods ranged from 1 to 3 years, and the majority of patients (range 56-73%) were alive at the end of the studies. Analysis was performed in one study to characterise factors associated with overestimation of survival. 16 In three papers, patients were asked about their preferences around treatment aims, and analyses performed looking at how these responses correlated with self-estimated life expectancy. 17 19 20 One paper used repeat measures to examine how self-estimated life expectancy changed with disease course.
14 Self-estimated life expectancy compared with observed survival Comparisons of self-estimated life expectancy and observed survival were reported in five papers from four studies 14-16 18 20 and one abstract. 21 In general, selfestimated life expectancy exceeded observed survival. The only example of self-estimated life expectancy consistent with survival was 1-year mortality in patients with ESRF. 20 81% of patients thought they had a better than 90% chance of being alive at 1 year. Observed survival was 93%. In comparison, 96% of patients believed they had a better than 50% chance of being alive at 5 years, but 44% had died within just 23 months. In one study, only 5% of patients with HF estimated their life expectancy to be 3 years or less, but observed mortality was 29% after a median follow-up of 3.1 years. 16 Among patients with advanced HF, 3 of 56 (5%) patients expected to live <1 year, but 17 (30%) were dead in this period. 15 Furthermore, 6 of 79 (8%) patients with COPD in the same study predicted their life expectancy to be <1 year; 21 (27%) died. When interviewed within the 90 days before they died, only 2 of 16 patients predicted their life expectancy to be less than a year. 14 In the study published only as an abstract, 64% of patients with HF expected to live for longer than 2 years, but at a mean follow-up of 13 months 40% had died, been transplanted or required a left-ventricular assist device. 21 Patient numbers were too low in one study to draw conclusions from observed survival. 18 Self-estimated life expectancy compared with model predictions of survival In the only study that used a validated model 23 to predict survival, self-estimated life expectancy exceeded model predictions. 16 The median self-estimated life expectancy for 122 patients with HF was 13 years and the median model-predicted life expectancy was 10 years. There was no significant relationship between self and model-predicted life expectancy. The median ratio between self-estimated and model-estimated life expectancy was 1.4; indicating a 40% overestimation. Self-estimates of life expectancy were more similar to model predictions based on age and gender alone than to predictions taking heart disease into account.
Self-estimated life expectancy compared with clinician-estimated life expectancy Four papers from three studies reported comparisons of self-estimated and clinician-estimated life expectancy. 14 15 18 20 Estimates agreed poorly, with a tendency for patients to be more optimistic about life expectancy than their clinicians. Estimating 1-year and 5-year survival, patients with ESRF on dialysis were significantly more optimistic than their nephrologists. 20 Among patients with COPD and HF, agreement between patients and their clinicians about whether the patient would survive 2 years was poor, with a Kappa statistic of 0.22. 15 Numbers of patients in one study were too small for any conclusions to be drawn. 18 
Other findings
Younger age, greater disease severity and lower levels of depression were independently associated with selfestimated life expectancy exceeding model predictions among patients with HF. 16 Patients receiving haemodialysis who thought they had a ≥90% chance of being alive in 1 year were significantly more likely to choose lifeextending therapy (44%) than patients who reported a <90% chance (9%). 20 Patients with advanced COPD and HF serially interviewed over 1 year showed no evidence of adjusting their self-estimated life expectancy with disease progression.
14 Only one patient of 135 revised their estimate from >1 year to <1 year, while mortality was 28% over this period. Three studies found that patients with HF make estimates of their life expectancy that are likely to be optimistic but did not present any other validated prediction or measure of survival. 17 19 22 One found patients who anticipated shorter survival to be more willing to trade longevity for improved quality of life than those who predicted longer lives. 19 The other study did not demonstrate this. 17 One study was published only as an abstract and had insufficient numbers of patients to draw conclusions. 22 
DISCUSSION
Practice guidelines advocate considering prognosis when making decisions with patients who have chronic disease 24 25 and promote sharing survival statistics with patients. 26 27 There is evidence from cancer 14 28 29 and non-cancer 15 informed decisions between them. Hospitalised individuals are more likely to want cardiopulmonary resuscitation if they expect to survive their illness, even if these expectations are improbable. 2 32 Patients with terminal cancer who are optimistic about their prognosis are more interventional in their choice of medical therapy. 1 It is conceivable that behaviours as diverse as adherence to preventative drugs and deciding whether to make a will could be influenced by how long an individual expects to live.
In this systematic review of self-estimated life expectancy in chronic disease, individuals' estimates exceeded nearly all predictions and measures of survival; including model-predicted and observed survival. Patients with non-cancer chronic disease may have survival expectations that markedly exceed outcomes. These expectations might lead some patients to make health decisions and life choices that they would not if their predictions were more realistic. Patients were more optimistic than their clinicians when estimating life expectancy. Only in one instance (1 year survival in ESRF) were patients' estimations in keeping with actual survival, and more accurate than their physicians', but by 2 years this had reversed. 20 Whether this time-based effect represents a reproducible feature of perceived versus clinicianpredicted life expectancy would require replication in other disease groups. Patients with HF and COPD were approximately three times more likely to be dead within the year than they predicted. 15 Life expectancy was overestimated by a median of 40% by patients with HF, when compared with a validated model; equating to 3 years of life for the average patient. 16 Self-estimates were more in keeping with the life expectancy of matched adults without chronic disease. 16 There was evidence that no meaningful adjustment in expected survival is made by patients approaching the ends of their lives.
14 If the findings of this review reflect pervasive overestimation of life expectancy by individuals with chronic disease, there are several possible explanations. First, patients might never be informed that their condition could affect their life expectancy. Such individuals are likely to base survival expectations on familial and media exposure, influenced by hopefulness and 'fighting spirit'. Others might receive overoptimistic forecasts; either due to methods of estimation, or adjustment by the communicating clinician. Finally, patients might be provided with appropriate quantitative estimates, but instead form more favourable personal predictions.
These findings are compatible with the oncology literature. Most patients with cancer want to discuss life expectancy, although desire for quantitative estimation varies. 33 Despite this, many report not having discussed prognosis or are found to misunderstand the status of their disease, the aim of their treatment and their prognosis. 3 Overestimation of the chances of cure and survival is common, even if disease is incurable and where individuals report having discussed prognosis with their clinician. 34 The prognosis in non-cancer disease can be equivalently poor to that seen in malignancy. [8] [9] [10] End of life care differs by diagnosis, so caution must be taken when generalising findings from cancer to non-cancer disease settings. 13 35 None of the patients with ESRF in this review recalled discussing life expectancy with their clinician; their nephrologists reported having such conversations with only 3% of the patients. 20 Sixty-three per cent of patients with HF in one study did not recall having spoken with their physician about their prognosis following the diagnosis of HF and only 36% believed HF would shorten their life. 16 Only 22% of patients in one study with advanced COPD and HF recalled having been told that they could die of their disease and only 1% recalled having been given an estimate of how long they might live. 15 Prognostic discussions between patients with noncancer chronic disease and their clinicians may be infrequent. In a systematic review of the literature, it was found that most patients with COPD report that they have never had an end of life care discussion with a healthcare provider. 36 Interviews with individuals with ESRF suggest that while early information is beneficial, the daily focus on clinical care and a reliance on clinicians to initiate end of life care discussions act as barriers to advance planning. 31 Interviews with patients with ESRF and their clinicians suggest that nephrologists tend to avoid discussions about the future. 37 The evidence for prognostic discussions between patients with cancer and their clinicians is varied. 3 Discussions are more likely to be triggered by the clinician than the patient and are probably infrequent among individuals with advanced malignancy. 3 Where discussions occur, they are often unclear and both parties tend to avoid acknowledging or discussing prognosis. 38 There are boundaries to clinicians initiating prognostic discussions, such as fear of causing anxiety or destroying hope; 39 uncertainty about the validity, accuracy or precision of estimates 40 and lack of experience and training in communication skills. 41 A better understanding is needed of the interaction between survival expectations and behaviour in chronic disease. If compelling evidence is found showing overestimation of survival leads patients to make decisions out of keeping with their likely future, approaches to adjusting such expectations could be developed. Inclusion of validated methods for estimating and communicating prognosis in decision support materials may be one way of increasing the frequency of prognostic discussions. Research into the acceptability and best methodology for facilitating these discussions should be a research priority. Some patients will not feel able to discuss prognosis, so clinicians must take care to elucidate preferences for information. However, clinicians should continue to provide opportunities for prognostic discussion, since preferences may change over time and with disease progression. In other diseases such as breast cancer, the use of prognostic models and decision tools has been shown to increase understanding of prognosis and treatment options, leading to higher degrees of satisfaction. 42 Validated tools to help predict survival in chronic disease are available, 23 43-45 but there is no evidence that these are widely employed. Only a minority are provided with accessible calculators (box 1). Studies are needed to examine how prognostic tools can be used in the clinical setting. 46 It is possible that clinical practice has not kept pace with the paradigm shift towards information sharing with patients. Even where prognostic discussions happen, survival statistics may be misrepresented or censored. 47 In one study included in this review, nephrologists provided estimates of life expectancy for 89% of the interviewed patients, but reported they would withhold over half of these estimates in clinical practice. 20 The ability to make firm conclusions from the literature was highly limited by the lack of available evidence. The literature comes largely from single centre cohorts and is of medium to low quality. Data from diseases other than HF is extremely limited, and those with the most advanced disease were under-represented. Included studies are likely to have come from centres where prognostication is considered important. We excluded studies including only participants with cancer, HIV/AIDS, congenital heart disease, cystic fibrosis and organ transplant. Cancer literature has been well summarised, 3 but it is possible that these excluded conditions could have provided additional insight. We are aware of only one paper that would have been included without this exclusion, showing that young adults with congenital heart disease expect to live almost as long as their healthy peers. 48 There is no standardised or validated method for assessing self-estimated life expectancy, and it is likely that responses are influenced by methodology. Additionally, asking a patient how long they expect to live facilitates a quantitative assessment of their understanding but does not provide information on how such perceptions are formed and influenced. Large numbers of patients were excluded from the studies or were unable or unwilling to estimate their own life expectancy, with the potential to introduce bias. In addition, many patients were excluded on grounds of language skills or cognitive impairment. These excluded individuals are likely to find discussing and understanding prognosis particularly challenging, and this undermines the relevance of the included studies to a population of patients with chronic disease, in whom cognitive impairment is common. All the studies reporting actual survival were limited by short follow-up times and low numbers of deaths in the cohorts. Hospitalised patients were under-represented in the included studies. It is feasible that survival expectations are different during periods of acute illness requiring admission; the point at which critical decisions about healthcare are often made. There is evidence to suggest that overestimation of survival persists in these situations however; in malignant and non-malignant disease. 2 32 34 49 None of the included studies had a healthy reference group. Overestimation of life expectancy cannot, therefore, be presumed a phenomenon limited to patients with disease. A recently published prospective cohort study provides some evidence to suggest self-estimation of survival might be different among individuals unselected for chronic disease. Approximately half of participants made predictions of their life expectancy consistent with those from a statistical model. 50 Where predictions were inaccurate, they were approximately three times more likely to be underestimates than overestimates. Overestimation increased with age, but it is unclear whether this represented an independent effect of ageing on subjective life expectancy, or confounding by the increased prevalence of disease. It is possible that general population studies of self-estimated life expectancy could be analysed for differences between individuals with and without disease.
CONCLUSIONS
Patients with non-cancer chronic disease may have survival expectations that markedly exceed outcomes. These expectations might lead some patients to make health decisions and life choices that they would not if their predictions were more realistic. A better understanding is needed of the interaction between survival expectations and behaviour in chronic disease. If compelling evidence is found showing overestimation of survival leads patients to make decisions out of keeping with their likely future, approaches to adjusting such expectations could be developed. Meanwhile, clinicians caring for patients with chronic disease must make attempts to elucidate what prognostic information each patient already knows, wants to know and might benefit from knowing. Appropriate information should then be shared in a form that the patient can use to inform their decisions.
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Box 1 Online calculators available for predicting survival in chronic disease
The BODE index: 4-year survival in COPD ▸ http://www.qxmd.com/calculate-online/respirology/bode-index The Seattle Heart Failure Model: 1, 2 and 3-year survival in HF ▸ https://depts.washington.edu/shfm/ Integrated Prognostic Model: 6-month mortality on haemodialysis ▸ http://www.qxmd.com/calculate-online/nephrology/predicting-6-month-mortality-on-hemodialysis
